Interline Therapeutics, a Foresite Labs incubated company focused on systematically elucidating protein communities to define molecular mechanisms of disease, announced today that the company has raised $92 million. Foresite Capital and ARCH Venture Partners co-led the financing, which will be used to expand the research platform and advance six preclinical therapeutic programs.

Interline Therapeutics is a drug discovery company focused on systematically elucidating protein communities to define molecular mechanisms of disease. Interline was incubated by Foresite Labs and is headquartered in South San Francisco, CA. For more information, please visit www.interlinetx.com.